The Kettering Health Network Pharmacy and Therapeutics (P&T) Committee has received requests to evaluate the use of the non-formulary agent, tocilizumab (Actemra) for cytokine release syndrome in COVID-19 patients. After careful review of the available efficacy literature, drug safety data, and professional society recommendations, it is our recommendation that tocilizumab NOT be added to formulary at this time.
In accordance with the current IDSA guidelines, tocilizumab therapy for COVID-19 will be limited to clinical trial participation only. The network is actively pursuing opportunities to participate in investigational treatment studies.
KHN P&T will continue to evaluate non-formulary agents for formulary status in the setting of COVID-19 as new information becomes available.